Instrument Inactif

Autres langues Misonix, Inc.

Actions

MSON

US6048711039

Equipement, fournitures et distribution médicale

Autres langues

26/04/22	Misonix, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021
01/11/21	Misonix, Inc.(NasdaqGM:MSON) dropped from S&P TMI Index
01/11/21	Misonix, Inc.(NasdaqGM:MSON) dropped from S&P Global BMI Index
29/10/21	MISONIX INC : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
29/10/21	Misonix, Inc.(NasdaqGM:MON) dropped from NASDAQ Composite Index
29/10/21	Bioventus Inc. completed the acquisition of Misonix, Inc. from Stavros G. Vizirgianakis, SV Life Sciences Fund VI, L.P. and Sv Life Sciences Fund VI Strategic Partners, L.P., funds managed by SV Health Investors, LLC, 1315 Capital, LLC and others.
26/10/21	MISONIX INC : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
18/10/21	MISONIX INC : Other Events (form 8-K)
02/09/21	MISONIX : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
02/09/21	Misonix : Q4 Net Loss Narrows, Revenue Surges
02/09/21	MISONIX : REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS (Form 8-K)
02/09/21	Misonix : Earnings Flash (MSON) MISONIX Posts Q4 Revenue $19.7M
02/09/21	Misonix : Reports Fourth Quarter and Fiscal Year 2021 Financial Results
02/09/21	Misonix, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2021
12/08/21	MISONIX INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
12/08/21	Misonix, Inc. Announces Nonrenewal of Allan Staley as President and Named Executive Officer
31/07/21	MISONIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Misonix, Inc. - MSON
30/07/21	Misonix : Bioventus to Acquire Misonix in Cash-and-Stock Deal Valued at $518 Million
30/07/21	NASDAQ 100 : Top Midday Gainers
29/07/21	Misonix : FORM OF VOTING AND SUPPORT AGREEMENT (Form 8-K)
29/07/21	MISONIX INC : Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)
29/07/21	Misonix : Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix
29/07/21	Misonix, Inc. Reported Revenue Results for the Fiscal Fourth Quarter and Full Year 2021
29/07/21	Misonix Reports Preliminary Fiscal 2021 Fourth Quarter and Full Year Revenue Results
29/07/21	Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. from Stavros G. Vizirgianakis, SV Life Sciences Fund VI, L.P. and Sv Life Sciences Fund VI Strategic Partners, L.P., funds managed by SV Health Investors, LLC, 1315 Capital, LLC and others for approximately $500 million.